Cyclerion Therapeutics Inc (NAS:CYCN)
$ 2.7156 0.6056 (28.7%) Market Cap: 6.79 Mil Enterprise Value: 1.09 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 46/100

Cyclerion Therapeutics Inc Pipeline Update Webinar Corporate Call Transcript

Apr 27, 2021 / 12:00PM GMT
Release Date Price: $51.2 (-17.95%)
Peter M. Hecht
Cyclerion Therapeutics, Inc. - CEO & Director

Good morning. Welcome. We're very pleased that you've joined us this morning. We're looking forward to the next hour in spending some time with you talking about the progress we're making with the development work that we're doing at Cyclerion. We're a CNS focused team, and we all share a very big passion to develop drugs to restore cognitive function. We're going to talk through the scientific foundations of our efforts and why our recent clinical results demonstrating a rapid effect on multiple biomarkers associated with cognition are propelling our portfolio forward in several clinical populations associated with cognitive impairment, including a subpopulation of Alzheimer's called ADv, where we just got our IND cleared by the FDA, so we're pleased to share the details of that -- and design of that study with you today, and we'll be initiating the enrollment soon. And these first studies are just the beginning, the early days of what has the potential we believe of a tremendous opportunity to help millions of people globally suffering

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot